Abstract-Chronic aldosterone administration increases glomerular filtration rate, whereas inhibition of mineralocorticoid receptors (MRs) markedly attenuates glomerular hyperfiltration and hypertension associated with primary aldosteronism or obesity. However, the mechanisms by which aldosterone alters glomerular filtration rate regulation are poorly understood. In the present study, we hypothesized that aldosterone suppresses tubuloglomerular feedback (TGF) via activation of macula densa MR. First, we observed the expression of MR in macula densa cells isolated by laser capture microdissection and by immunofluorescence in rat kidneys. Second, to investigate the effects of aldosterone on TGF in vitro, we microdissected the juxtaglomerular apparatus from rabbit kidneys and perfused the afferent arteriole and distal tubule simultaneously. Under control conditions, TGF was 2.8Ϯ0.2 m. In the presence of aldosterone (10 Ϫ8 mol/L), TGF was reduced by 50%. The effect of aldosterone to attenuate TGF was blocked by the MR antagonist eplerenone (10 Ϫ5 mol/L). Third, to investigate the effect of aldosterone on TGF in vivo, we performed micropuncture, and TGF was determined by maximal changes in stop-flow pressure P sf when tubular perfusion rate was increased from 0 to 40 nL/min. Aldosterone (10 Ϫ7 mol/L) decreased ⌬P sf from 10.1Ϯ1.4 to 7.7Ϯ1.2 mm Hg. In the presence of L-NG-monomethyl arginine citrate (10 Ϫ3 mol/L), this effect was blocked. We conclude that MRs are expressed in macula densa cells and can be activated by aldosterone, which increases nitric oxide production in the macula densa and blunts the TGF response. Aldosterone, at levels that mimic those found in pathophysiological conditions, such as primary aldosteronism, alters regulation of renal hemodynamics. Chronic aldosterone infusion, at rates that raise plasma concentration to 5 to 6 times normal, increased glomerular filtration rate (GFR) and renal plasma flow by Ϸ20%. 2 Likewise, increased GFR has been observed in patients with primary aldosteronism before the development of renal injury and nephron loss. 3,4 Previous studies have also shown that MR antagonism almost completely prevented the glomerular hyperfiltration associated with development of obesity in dogs fed a high-fat diet. 5 The mechanisms by which hyperaldosteronism increases GFR are poorly understood but are unlikely to be caused solely by volume expansion, because aldosterone infusion causes only small increases in extracellular fluid volume attributed rapid "escape from sodium retention." 2 Also, increased arterial pressure cannot fully explain the rise in GFR, because servocontrol of renal perfusion pressure did not prevent glomerular hyperfiltration during chronic aldosterone infusion. 2 Normal physiological levels of aldosterone may also influence GFR regulation, because MR antagonism decreased GFR by Ϸ20% in normal, lean dogs while causing only small effects on arterial pressure and sodium balance. 5 One explanation for the effects of MR activation on GFR is altered tubuloglomerular feedback (TGF). If aldosterone resets TGF, this would tend to increase GFR and permit increased distal NaCl delivery. Such an effect could have important adaptive value, because stimulation of sodium reabsorption in the collecting tubules by aldosterone excess, as occurs in primary aldosteronism, would necessitate increased NaCl to these tubular segments to maintain NaCl balance if intake remained unchanged. Conversely, inhibition 
A ldosterone-mediated activation of mineralocorticoid receptors (MRs) plays a key role in water and electrolyte homeostasis through genomic effects on the colon and renal epithelial cells, especially the principal cells and intercalated cells of the late distal tubules, collecting tubules, and collecting ducts. However, aldosterone may also have important effects on other target tissues through genomic, as well as nongenomic actions. 1 Aldosterone, at levels that mimic those found in pathophysiological conditions, such as primary aldosteronism, alters regulation of renal hemodynamics. Chronic aldosterone infusion, at rates that raise plasma concentration to 5 to 6 times normal, increased glomerular filtration rate (GFR) and renal plasma flow by Ϸ20%. 2 Likewise, increased GFR has been observed in patients with primary aldosteronism before the development of renal injury and nephron loss. 3, 4 Previous studies have also shown that MR antagonism almost completely prevented the glomerular hyperfiltration associated with development of obesity in dogs fed a high-fat diet. 5 The mechanisms by which hyperaldosteronism increases GFR are poorly understood but are unlikely to be caused solely by volume expansion, because aldosterone infusion causes only small increases in extracellular fluid volume attributed rapid "escape from sodium retention." 2 Also, increased arterial pressure cannot fully explain the rise in GFR, because servocontrol of renal perfusion pressure did not prevent glomerular hyperfiltration during chronic aldosterone infusion. 2 Normal physiological levels of aldosterone may also influence GFR regulation, because MR antagonism decreased GFR by Ϸ20% in normal, lean dogs while causing only small effects on arterial pressure and sodium balance. 5 One explanation for the effects of MR activation on GFR is altered tubuloglomerular feedback (TGF). If aldosterone resets TGF, this would tend to increase GFR and permit increased distal NaCl delivery. Such an effect could have important adaptive value, because stimulation of sodium reabsorption in the collecting tubules by aldosterone excess, as occurs in primary aldosteronism, would necessitate increased NaCl to these tubular segments to maintain NaCl balance if intake remained unchanged. Conversely, inhibition of NaCl reabsorption in distal nephron segments by MR antagonism would require decreased distal delivery of NaCl, possibly through reductions in GFR, to achieve salt balance if intake was unaltered. TGF resetting could be an important mechanism for mediating reduced GFR and distal NaCl delivery during MR antagonism.
Despite the potential adaptive value of TGF resetting and glomerular hyperfiltration in offsetting the renal sodium retaining actions of aldosterone and MR activation, this effect has been proposed to contribute to renal injury in patients with primary aldosteronism. 4 Although MR activation by aldosterone is recognized to be an important cause of glomerular hyperfiltration, the mechanisms involved are poorly understood. In preliminary studies we found significant MR expression on macula densa (MD) cells, suggesting a potential role in TGF. To our knowledge, the direct effects of aldosterone on TGF have not been reported previously. Therefore, in the present study we tested the hypothesis that aldosterone suppresses TGF through MR activation in MD cells. Multiple approaches were used to test this hypothesis, including investigation of the effects of aldosterone on TGF using microdissected and perfused juxtaglomerular apparatus (JGA) in vitro and micropuncture studies in vivo. Our studies reveal that aldosterone reduces TGF by stimulation of nitric oxide (NO) synthesis and that this effect is mediated through activation of MR.
Methods
All of the procedures and experiments were approved by the institutional animal care and use committee at the University of Mississippi Medical Center. All of the chemicals were purchased from Sigma (St Louis, MO) except as indicated.
Microperfusion: Isolation and Microperfusion of the Rabbit Afferent Arteriole and Attached MD
We used methods similar to those we described previously 6 (please see the online-only Data Supplement). After the 30-minute equilibration period, the MD perfusate was switched from 10 to 80 mmol/L of NaCl at a rate of 40 nL/min, and luminal diameter of the afferent arteriole (Af-Art) perfused at 60 mm Hg was measured for 5 minutes. We used the average change in diameter of the Af-Art as our control TGF response. Then the MD perfusate was switched back to 10 mmol/L of NaCl. To study the effect of aldosterone on regulation of the TGF response in vitro, aldosterone (10 Ϫ8 mol/L) was added to the tubular perfusate for 15 minutes, and a second TGF response was measured. To determine whether the aldosteroneinduced TGF alteration could be inhibited by MR blockade, a selective MR antagonist, eplerenone, 10 Ϫ5 mol/L, was added to the tubular perfusate 30 minutes before aldosterone administration in separate experiments, and the above protocol was repeated.
Micropuncture: Animal Preparation
Male, Sprague-Dawley rats, 250 to 350 g, were used. Methods for animal preparation were similar to those published previously 7 (please see the online-only Data Supplement). TGF was determined by maximum changes of stop-flow pressure (P sf ) when increasing tubular perfusion rate from 0 to 40 nL/min. First, the nephron was perfused with artificial tubular fluid containing vehicle for 3 to 5 minutes to get the initial measurement of P sf. Next, it was perfused for 10 minutes with vehicle or aldosterone (10 Ϫ7 or 10 Ϫ8 mol/L). In other experiments, to determine the role of NO in aldosteroneinduced TGF alteration, L-NG-monomethyl arginine citrate (L-NMMA; Cayman Chemical, Ann Arbor, MI), 10 -3 mol/L, was added into the perfusate, and the protocol above was repeated.
Laser Capture Microdissection and RT-PCR
Laser capture microdissection (LCM) and RT-PCR were used to isolate MD cells in Sprague-Dawley rats and to measure MR mRNA with methods that we have described previously 8 (please see the online-only Data Supplement).
Immunofluorescence
The MR antibodies were developed and characterized as reported previously. 9 An antibody for the Na ϩ -K ϩ -2Cl transporter (NKCC2) was a gift from Dr Pablo Ortiz at Henry Ford Hospital (Detroit, MI). Rat kidney sections were double stained with MR and NKCC2 primary antibodies and subsequent fluorescent secondary antibodies and observed under the Nikon microscope (please see the onlineonly Data Supplement).
Cell Culture and NO Measurement
Experiments were undertaken, using MMDD1 cells, an MD-like cell line (kindly provided by Dr J. Schnermann, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD) in a manner similar to our previously described studies. 8, 10 The cellpermeable fluorescent NO indicator, 4,5-diaminofluorescein diacetate, 10 mol/L, was used to measure NO before incubation and 15 minutes after incubation with aldosterone (10 Ϫ8 mol/L; please see the online-only Data Supplement).
Statistical Analysis
Data were collected as repeated measures over time under different conditions. We tested only the effects of interest, using ANOVA for repeated measures and a post hoc Fisher least-significant difference test or a Student paired t test when appropriate. The changes were considered to be significant if PϽ0.05. Data are presented as meanϮSEM. Figure 1 shows immunofluorescent results and positive staining for MR in the MD with intensity similar to that in thick ascending limbs but weaker than in distal tubules or medullary collecting ducts. We also used an NKCC2 antibody to mark MD and the thick ascending limbs. Note that MR is expressed in MD, as well as in thick ascending limbs and distal tubules, whereas NKCC2 is expressed in thick ascending limbs and MD but not in distal tubules.
Results

MR Expression in the MD
To confirm MR expression in MD, we also used LCM to microdissect MD cells from frozen rat kidney sections and performed RT-PCR on the captured cells to measure mRNA expression. As shown in Figure 2A , the anatomic location and morphology of MD cells were identified with the LCM microscope before dissection. The cells were then thawed and combined with the membrane ( Figure 2B ), and cells were removed by lifting the membrane ( Figure 2C ). Figure 2D indicates that MR mRNA was expressed in microdissected MD cells. The negative control did not contain cDNA. Thus, we confirmed MR expression in the MD with 2 independent methods.
Aldosterone Blunts In Vitro TGF Measured With Microperfusion
To test the direct effect of aldosterone on TGF, we microdissected and perfused rabbit Af-Arts and glomeruli with the attached MD. As shown in Figure 3A , when sodium concentration in tubular perfusate was increased from 10 to 80 mmol/L, the Af-Art diameter decreased from 18.8Ϯ0.3 to 16.0Ϯ0.4 m, and the TGF response, as shown in Figure 3B , was 2.8Ϯ0.2 m. In the presence of aldosterone, the Af-Art diameter decreased from 19.9Ϯ0.5 to 18.5Ϯ0.5 m, and the TGF response was thus reduced by 50% to only 1.4Ϯ0.4 m (nϭ10; PϽ0.05). These data indicated that aldosterone blunted TGF in vitro.
To determine the role of MR in the acute effect of aldosterone on TGF, eplerenone (10 Ϫ5 mol/L), a selective MR antagonist, was used. As shown in Figure 3C , eplerenone was added in the tubular perfusate for 30 minutes and present during the rest of the experiment. When sodium concentration in tubular perfusate was increased from 10 to 80 mmol/L, the Af-Art diameter decreased from 18.9Ϯ0.4 to 16.1Ϯ0.7 m. TGF, as shown in Figure 3D , was 2.8Ϯ0.7 m. Then, the tubular perfusate was switched back to 10 mmol/L of NaCl, and aldosterone was added for 15 minutes. When we increased tubular NaCl to 80 mmol/L in the presence of aldosterone, the Af-Art diameter decreased from 18.9Ϯ0.7 to 16.5Ϯ0.3 m. TGF was, thus, 2.4Ϯ0.5 m (nϭ5). These data indicate that the effect of aldosterone on TGF was attenuated by MR antagonism, suggesting that the inhibitory effect of aldosterone on TGF was primarily mediated via MR activation.
Aldosterone Blunts In Vivo TGF Measured by Micropuncture
We performed micropuncture to test whether aldosterone affects the TGF response in vivo. The results of time control experiments are shown in Figure 4A (nϭ4 rats/7 tubules). When the tubular perfusion rate of vehicle was increased from 0 to 40 nL/min, P sf decreased from 38.9Ϯ1.3 to 30.1Ϯ1.1 mm Hg, and the change in P sf (⌬P sf ), used as the TGF response, was 8.8Ϯ0.9 mm Hg. Then we stopped tubular perfusion and waited for the P sf to return to baseline, which was 38.2Ϯ1.3 mm Hg. When we increased tubular perfusion rate to 40 nL/min again, P sf decreased to 30.0Ϯ1.5 mm Hg. ⌬P sf was 8.1Ϯ1.0 mm Hg. There was no significant difference between the 2 TGF responses, indicating that the TGF response is reversible and was a suitable control for the following experiments.
We tested whether aldosterone had any effect on TGF in vivo by adding aldosterone to the tubular perfusate and measuring TGF. When tubular perfusate was increased from 0 to 40 nL/min with vehicle, P sf decreased from 39.7Ϯ2.1 to 31.0Ϯ2.9 mm Hg. The ⌬P sf was 9.1Ϯ1.0 mm Hg. Then we stopped tubular perfusion and waited for the P sf to return to baseline. When we increased tubular perfusate to 40 nL/min in the presence of 10 Ϫ8 mol/L of aldosterone, P sf decreased from 38.4Ϯ2.1 to 29.7Ϯ2.1 mm Hg. The ⌬P sf was 9.0Ϯ0.9 mm Hg. There was no significant difference in TGF with and without aldosterone ( Figure 4B ; nϭ4 rats/7 tubules). Then we increased the concentration of aldosterone to 10 Ϫ7 mol/L in the above experiments. As shown in Figure 4C , when perfused with vehicle only (control), P sf was reduced from 38.8Ϯ1.3 to 28.7Ϯ1.9 mm Hg, and ⌬P sf was 10.1Ϯ1.4 mm Hg. In the presence of aldosterone, the P sf was reduced from 39.3Ϯ1.6 to 31.5Ϯ1.6 mm Hg, and ⌬P sf was 7.7Ϯ1.2 mm Hg (nϭ4 rats/9 tubules; PϽ0.05). Figure 4D shows a representative experiment demonstrating the changes of stop flow pressure responding to vehicle or aldosterone perfusion. Arrows indicate where P sf was measured. These data suggest that aldosterone blunted the TGF response in vivo.
To determine whether NO is involved in aldosteroneinduced TGF inhibition, we used L-NMMA, a nonselective NO synthase (NOS) inhibitor in the lumen. First, L-NMMA (10 Ϫ3 mol/L) alone was tested in control experiments. When tubular perfusate was increased from 0 to 40 nL/min with L-NMMA, P sf decreased from 36.8Ϯ2.4 to 24.7Ϯ2.7 mm Hg, and ⌬P sf was 12.1Ϯ1.4 mm Hg. In a repeat of control conditions, after P sf returned to baseline, tubular perfusion rate was increased from 0 to 40 nL/min, and P sf decreased from 36.4Ϯ2.3 to 22.9Ϯ3.1 mm Hg. ⌬P sf was 13.6Ϯ 1.6 mm Hg ( Figure 5A ; nϭ5 rats/8 tubules; PϽ0.05). In the next group of experiments, aldosterone, 10 Ϫ7 mol/L, was added to the tubular perfusate in the presence of L-NMMA. When perfused with L-NMMA alone, P sf decreased from 37.5Ϯ1.9 to 24.3Ϯ1.7 mm Hg, and ⌬P sf was 13.2Ϯ1.4 mm Hg. In the presence of aldosterone, P sf decreased from 37.5Ϯ1.7 to 21.8Ϯ1.8 mm Hg, and ⌬P sf was 15.7Ϯ1.0 mm Hg. The changes between the first and second TGF responses in the absence and presence of aldosterone were not significantly different. As shown in Figure 5B , the effect of aldosterone on TGF was totally blocked when NO was inhibited (nϭ4 rats; nϭ7 tubules). We also compared the difference between TGF response to aldosterone alone (Figure 4C ) and aldosterone plus L-NMMA ( Figure 5B). The difference was significant (PϽ0.01). These data suggest that NO was involved in mediating the acute effect of aldosterone on TGF, because blockade of NOS totally prevented the attenuation of TGF by aldosterone.
Aldosterone Stimulates NO Production in Cultured MD Cells
To test whether aldosterone enhances NO generation by the MD cells, we loaded MMDD1 cells with 4,5-diaminofluorescein diacetate to measure NO generation with and without aldosterone. In basal conditions, the rate of NO generation was 40.4Ϯ4.3 U/min. After adding aldosterone for 15 minutes, the rate of NO production increased significantly to 644.1Ϯ118.5 U/min (Figure 5C ; nϭ16; PϽ0.01 versus basal). In time control experiments only with vehicle, the rate of increase in NO generation was 45.9Ϯ5.2 U/min at basal and 53.4Ϯ6.1 U/min 15 minutes later (nϭ11).
Discussion
A novel finding of the present study is that mRNA and protein for MR are expressed in the MD cells. Second, we found that aldosterone blunted the TGF response both in anesthetized rats in vivo and in microperfused JGA in vitro. Third, the MR antagonist eplerenone abolished aldosteroneinduced TGF inhibition. Fourth, NOS inhibition restored the blunted TGF. Fifth, aldosterone markedly increased NO generation by MMDD1 cells. Taken together these data suggest that aldosterone attenuates TGF by a MR-mediated event resulting from release of NO by the MD.
Previous studies using autoradiographic methods and immunostaining have found MR in distal tubules, connecting and cortical collecting tubules, and in medullary and papillary collecting ducts. 11, 12 MR was also found in the thick ascending limb of the loop of Henle using RT-PCR 13 and recently in glomeruli by immunostaining. 14 Using highly specific anti- bodies, MR was found in connecting tubules, distal convoluted tubules, and cortical collecting tubules in rats, which is consistent with previous studies. 9, 12 However, we were surprised to find that substantial levels of MR are also expressed in MD cells, an observation that has not, to our knowledge, been reported previously. This finding was confirmed using LCM. In the past, it has been difficult to acquire sufficient MD cells to perform the necessary biochemical analysis and to study their cellular and molecular signaling mechanisms. The development of LCM, however, provides a tool to isolate and capture MD cells in sufficient numbers to measure mRNAs with single-cell RT-PCR. 8 In the present study, we used LCM to acquire MD cells and demonstrated mRNA for MR in the MD. These observations, when combined with our immunohistochemistry data, clearly indicate significant MR expression in MD cells.
Our results also indicate that aldosterone-mediated activation of MR in the MD has a functional role in altering TGF. Using in vitro microperfused JGA, as well as in vivo micropuncture experiments, we found that aldosterone attenuated TGF by Ϸ50%. This effect was completely reversed by blocking NO synthesis, indicating that NOS plays a primary role in TGF resetting by aldosterone. To our knowledge, there have been no previous reports of the direct effects of aldosterone on TGF. Only a few studies have been conducted to examine the effects of MR activation on renal hemodynamics. Arima et al 15, 16 showed that acute administration of aldosterone caused constriction in rabbit arterioles, and NOS inhibition further augmented this vasoconstriction. In contrast, Uhrenholt et al 17 found in renal afferent arterioles a vasodilator effect of aldosterone that was abolished by blockade of NOS. Schmidt et al 18 also found in human forearms that aldosterone caused vasodilation and increased blood flow, but after administration of L-NMMA, forearm blood flow significantly decreased during aldosterone infusion. Thus, although there is still controversy concerning the vascular effects of aldosterone, the signaling pathway consistently points to NO, which is consistent with our observation that the rapid effect of aldosterone on TGF is mediated by NO.
To further test whether aldosterone enhances NO generation in the MD, we measured NO generation in MMDD1 cells with a fluorescent dye. We found that aldosterone significantly enhanced NO generation by MMDD1 cells. We reported recently that aldosterone also stimulated superoxide generation in MMDD1 cells. 10 In that study we excluded the effect of NO by using L-arginine-free solutions. However, in the present study, L-arginine was present in solutions used for the experiments with MMDD1. Therefore, enzymes that generate both NO and superoxide should have been intact in the present study. The detection of either NO or superoxide should, therefore, reflect the net effect of the interaction between the NO and superoxide. A significant increase of NO was detected in MMDD1 cells stimulated by aldosterone, indicating that production of NO exceeded that of superoxide.
Our results also indicate that the effects of aldosterone to reduce TGF responses occur rapidly, within 10 minutes. When aldosterone functions through a genomic pathway, it couples with MR, and this product functions as a transcription factor. However, rapid nongenomic effects of aldosterone that do not require transcription or protein synthesis have also been reported in various tissues, such as the heart, colon, renal tubule, and vascular smooth muscle. 1 As early as 1958, the rapid action of aldosterone on urinary electrolyte excre- 
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In the presence of L-NMMA, the acute effect of aldosterone on TGF was blocked, with change of stop-flow pressure (⌬P sf ) decreased from 13.2Ϯ1.4 to 15.7Ϯ1.0 mm Hg (nϭ4 rats/7 tubules; *PϽ0.05). C, NO production induced by aldosterone was measured in MMDD1 cells with 4,5-diaminofluorescein diacetate (DAF-2 DA). In basal condition, the rate of increase in NO generation was 40.4Ϯ4.3 U/min (nϭ16). In the presence of aldosterone (10 Ϫ8 mol/L), the rate of NO production increased significantly to 644.1Ϯ118.5 U/min (nϭ16; *PϽ0.01 vs basal). In time control experiments, the rate of increase in NO generation was not significantly changed (nϭ11).
tion was reported to occur in 5 minutes. 19 In rat cortical collecting tubules, an aldosterone-induced ion influx occurred within 30 minutes. 20 A series of studies demonstrated that aldosterone acts within minutes to alter cellular pH and plasma membrane potassium conductance in various cell preparations by rapidly increasing net entry of Ca 2ϩ , activating membrane Na ϩ /H ϩ exchanger, and modulating K ϩ channel activity. [21] [22] [23] These effects were shown to be spironolactone insensitive and blocked by protein kinase C inhibitors. 24 The involvement of extracellular signal-regulated kinase 1/2 in the rapid nongenomic action was shown in MDCK cells 25 and in the renal medullary thick ascending limb of the loop of Henle. 26 The concentration of aldosterone required for rapid nongenomic effects has varied from subnanomolar up to 10 nmol/L. 27, 28 In the present study, the rapid effect of aldosterone occurred within 10 minutes in microperfused JGA and in micropuncture studies, suggesting that a nongenomic pathway may be involved. For the in vivo micropuncture studies, a higher dose of aldosterone was required to alter TGF. The reason for this is not clear but may be attributed to the micropuncture technique used. For example, effective concentrations of NOS inhibitors needed to inhibit TGF in renal micropuncture studies 7, 29 are usually higher than used in JGA microperfusion. 30 We cannot measure the actual concentration at the MD under current experimental settings but assume that the aldosterone concentration that actually reaches the MD cells is considerably less than the concentration in the proximal tubule when using micropuncture methods. Overall, our results suggest a novel mechanism by which aldosterone may influence GFR regulation through a nongenomic pathway.
In the present study we found that eplerenone completely blocked the effect of aldosterone on TGF, indicating that the effects are mediated through activation of MR. In agreement with our observations, the acute effects of aldosterone on small resistance mesenteric vessels 31 and renal afferent arterioles 17 are also mediated by activation of MR. However, it also has been reported that acute infusion of aldosterone had no effect on GFR both in humans 32 and animals. 33 These data do not necessarily contradict our findings in the present study. We found that aldosterone suppressed TGF and dilated Af-Art through the MR of the MD. Arima et al 15, 16 reported that aldosterone directly constricted the Af-Art. Therefore, the effect of acute injection of aldosterone may reflect the balance of effects on the MD, which would tend to inhibit TGF and raise GFR, and direct vasoconstrictor effects on Af-Art, which would tend to decrease GFR. The net acute effect of aldosterone could be unchanged GFR as a result of these offsetting effects. In secondary hyperaldosteronism, which is often associated with high levels of angiotensin II, which enhance TGF, the increased levels of aldosterone may serve to buffer the effect of angiotensin II on TGF and GFR.
Perspectives
Our observations provide a potential mechanism by which high levels of aldosterone may cause glomerular hyperfiltration, a risk factor for renal injury and chronic kidney disease, in patients with primary aldosteronism, as well as in obese subjects who have increased renal MR activation. 2, 34 Our results also indicate that the rapid effects of aldosterone on TGF are mediated through synthesis of NO at the MD and may provide a potential target for treating obesity hypertension and associated chronic kidney disease. Further studies are needed to elucidate the physiological and pathophysiological significance of this novel effect of aldosterone on TGF.
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